期刊文献+

合成多肽对结核分枝杆菌的胞内抑制作用 被引量:2

Intracellular Inhibitory Effect of Synthetic Peptide on Mycobacterium tuberculosis
下载PDF
导出
摘要 评价合成多肽对人白血病单核巨噬细胞THP-1的毒性和对结核分枝杆菌H37Rv的胞内抑菌作用。通过多肽的不同给药浓度,确定多肽对结核分枝杆菌的最小抑菌浓度(MIC),利用流式细胞术方法和MTT法检测2号肽对细胞THP-1的毒性作用,同时采用CFU方法检测其对H37Rv菌株的胞内抑菌作用。筛选的4条多肽均有抑菌作用,其中2号肽的最小抑菌浓度(MIC)最小,为200μg/m L。2号肽与细胞THP-1作用时,浓度为1 200μg/m L时表现出细胞毒性,与INH细胞毒性无显著差别。对于胞内H37Rv,2号肽抗结核作用具有时间和剂量依赖效应,随给药时间和剂量的增加H37Rv菌落数明显下降。2号肽不仅对巨噬细胞THP-1的毒性小,而且具有较好的抗胞内结核分枝杆菌活性,是一种潜在的抗结核新型药物。 This work is to evaluate the toxicity of the synthetic peptides on mononuclear macrophage THP-1 of human leukemia and the intracellular bacteriostatic effect on Mycobacterium tuberculosis H37 Rv. The minimum inhibition concentration(MIC)of the synthetic polypeptide on H37 Rv was determined through the different drug concentrations of poly-peptides. Then,the toxic effects of peptide-2 on THP-1 cells were detected using flow cytometry method and MTT method. The colony-forming unit(CFU)method was used for detecting intracellular bacteriostatic effect of peptide-2 on H37 Rv. Results were as below :All 4 screened peptides had bacteriostatic effect,the MIC of peptide-2 was 200 mg/m L. When the peptides-2 interacted with THP-1 cells,the cytotoxicity emerged at the concentration of 1200 mg/m L,meaning that there was no significant difference from INH's cytotoxicity. For intracellular H37 Rv,the anti-tuberculosis effects of peptide-2 presented time- and dose- dependent effect,the H37 Rv colony count was obviously decreased with the increase of the time and dose. In conclusion,not only has the peptide-2 small toxicity to the macrophage THP-1,but also solid intracellular anti-M. tuberculosis effect,and it can be a new and potential anti-tuberculosis drug.
出处 《生物技术通报》 CAS CSCD 北大核心 2016年第4期222-227,共6页 Biotechnology Bulletin
基金 吉林省科技发展计划项目(2008110)
关键词 合成多肽 结核杆菌 巨噬细胞 胞内抑菌 synthetic peptide Mycobacterium tuberculosis macrophage intracellular inhibitory
  • 相关文献

参考文献11

  • 1孙立春,COY David H.多肽药物研究进展[J].上海医药,2014,35(5):55-60. 被引量:12
  • 2Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China [ J ] . N Engl J Med, 2012, 366 ( 23 ) : 2161- 2170.
  • 3娄智勇.抗结核杆菌新药发现靶点蛋白的研究进展[J].生物物理学报,2011,27(10):828-838. 被引量:5
  • 4May EE, Leitao A, Tropsha A, et al. A systems chemical biology study of malate synthase and isocitratelyase inhibition in Mycobact- erium tuberculosis during active and NRP growth [ J 1 ~ Computati- anal Biology-and Chemistry, 2013, ( 47 ) : 167- 180.
  • 5Sharma V, Sharma S, Hoener zu Bentrup K, et al. Structure of isoci- trate lyase, a persistence factor of Mycobacterium tuberculosis [ J ] . Nat Struct Biol, 2000, 7 ( 8 ) : 663-668.
  • 6吴丛梅,李玲玲,关晓侠,刘新涛,陈吉,殷玉和.肽类化合物对H_(37)Ra抑制的优化筛选[J].生物技术通报,2014,30(8):196-201. 被引量:1
  • 7Craik D J, Fairlie DP, Liras S, et al. The future of peptide-baseddrugs [ J ] . Chem Biol Drug Des, 2013, 81 ( 1 ) : 136-147.
  • 8Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy [J]. Endoer Rev, 2003, 24 ( 4 ) : 389-427.
  • 9Craik D J, Fairlie DP, Liras S, et al. The future of peptidebased drugs [J] . Chem Biol Drug Des, 2013, 81 ( 1 ) : 136-147.
  • 10Liu XT, Sun B, Yin YH, et al. Optimization of phage heptapeptide library Screening process for developing inhibitors of the isocitrate lyase homologue from Mycobacterium tuberculosis [ J ] . Med Chen Res, 2014 ( 23 ) : 2543-2553.

二级参考文献112

  • 1赖煦卉,毕安定,王洪海.基于生物信息学的结核杆菌候选药靶基因的分析筛选[J].复旦学报(自然科学版),2004,43(6):1051-1055. 被引量:2
  • 2程颖,高美华.利用噬菌体肽库筛选与人CD59特异性结合的短肽[J].细胞与分子免疫学杂志,2006,22(2):164-166. 被引量:10
  • 3王旸,肖春玲.以异柠檬酸裂解酶为靶点筛选抗持留结核分枝杆菌药物[J].中国抗生素杂志,2007,32(7):391-395. 被引量:5
  • 4Qureshi H, Arif A, Alam E, Qadir N. Integration of informal medical practitioners in DOTS implementation to improve case detection rate. J Pak Med Assoc, 2010, 60: 33~37.
  • 5Bocchino M, Sanduzzi A, Bariffi F. Mycobacterium tuberculosis and HIV co-infection in the lung: Synergic immune dysregulation leading to disease progression. Monaldi Arch Chest Dis, 2000, 55: 381~388.
  • 6Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today, 2008, 13: 1090~1098.
  • 7Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem, 2008, 15: 1956~1967.
  • 8Godreuil S, Renaud F, Van de Perre P, Carriere C, Torrea G, Banuls AL. Genetic diversity and population structure of Mycobacterium tuberculosis in HIV-1-infected compared with uninfected individuals in Burkina Faso. Aids, 2007, 21: 248~250.
  • 9Rao M, Streur TL, Aldwell FE, Cook GM. Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. Microbiology, 2001, 147: 1017~1024.
  • 10Deckers-Hebestreit G, Altendorf K. The F0F1-type ATP synthases of bacteria: Structure and function of the F0 complex. Annu Rev Microbiol, 1996, 50: 791~824.

共引文献17

同被引文献29

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部